ArticleiScience2026
Multiscale cross modal fusion and cascaded signal propagation for drug target interaction prediction.
Article in iScience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Accurate prediction of drug-target interaction (DTI) facilitates the translation of lead compounds into clinical therapeutics. Despite progress in deep learning, two challenges remain: the representation gap between heterogeneous drug and protein modalities and insufficient use of complementary knowledge from pretrained encoders. To address these issues, we propose SF-DTI, a unified framework that integrates multi-encoder protein fusion, structure-semantic drug alignment, and progressive cross-modal refinement for DTI prediction. Specifically, SF-DTI captures global protein semantics from multiple pretrained protein language models, aligns graph-based structural features with pretrained semantic embeddings for drugs under subspace constraints, and progressively refines drug-protein interaction representations through cascaded cross-modal signal propagation. Experiments on six benchmark datasets under standard, cold-start, and cross-domain settings demonstrate that SF-DTI achieves competitive performance relative to seven state-of-the-art baselines across evaluation scenarios. These results suggest that SF-DTI is a promising framework for DTI prediction and may support virtual screening, drug repositioning, and drug discovery.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.